ABBV-400 (Not yet branded)

Other Medications

Experimental

Not available IV 2 Clinical Trials

EGFR MET

Description

ABBV-400 is an antibody-drug conjugate developed by AbbVie that targets both EGFR and MET receptor pathways in solid tumors including colorectal cancer. This dual-targeting approach is designed to overcome resistance mechanisms that commonly develop with single-target therapies in advanced CRC. The compound combines targeted antibody delivery with cytotoxic payload to selectively attack cancer cells expressing these receptors.

Mechanism of Action

ABBV-400 binds to both epidermal growth factor receptor (EGFR) and MET receptor tyrosine kinase, which are frequently overexpressed in colorectal cancer and drive tumor growth, invasion, and metastasis. Upon binding, the antibody-drug conjugate is internalized by the cancer cell, where it releases its cytotoxic payload directly into the tumor cell, causing targeted cell death while sparing normal tissues.

Molecular Targets

EGFR MET

Side Effects

Fatigue Nausea Diarrhea Decreased appetite Peripheral neuropathy Skin rash Infusion-related reactions Cytopenias

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06107413 Phase 2

Active, not recruiting

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

United States, Belgium, Germany, Israel, Japan, South Korea, Spain, Taiwan

NCT05029882 Phase 1

Active, not recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

United States, Australia, France, Israel, Japan, Poland, Puerto Rico, South Kore

Quick Info

Brand Name	Not yet branded
Category	Other Medications
Status	Experimental
EMA Status	Experimental
Spain Access	Not available
Administration	IV
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.